Apoptosis is critical to B-cell maturation, but studies of apoptotic regulation in primary 16 human B cells is lacking. Previously, we found that infecting human B cells with Epstein-Barr 17 virus induces two different survival strategies (Price et al., 2017). Here, we sought to better 18 understand the mechanisms of apoptotic regulation in normal and activated B cells. Using 19 intracellular BH3 profiling (iBH3), we defined the Bcl2-dependency of B-cell subsets from human 20 peripheral blood and tonsillar lymphoid tissue as well as mitogen-activated B cells. We found 21 that naïve and memory B cells were BCL-2 dependent, while germinal center B cells were MCL-22
Introduction 28
The maturation of B cells into antibody-secreting cells is critical to immunity and is 29 accomplished through either T-independent or T-dependent B-cell maturation. In T-independent 30 B-cell maturation, antigen binding to the B-cell receptor (BCR) stimulates extra-follicular naïve 31
and memory B cells to proliferate (Bortnick and Allman, 2013) . B cells can also be activated via 32 pathogen-associated molecular patterns (PAMPs), like CpG DNA, binding to Toll-like receptors 33 (TLR) (Bernasconi et al., 2002; Krieg et al., 1995) . Activated B cells can differentiate into short-34 lived plasmablasts or migrate into secondary lymphoid tissue to undergo T-dependent 35 maturation. In the germinal center (GC) reaction, the affinity for antigen is further refined through 36 somatic hypermutation and selection by apoptosis (Victora and Nussenzweig, 2012) . Ultimately, the humoral repertoire is shaped by apoptosis dependent on the multi-41 domain Bcl-2 family proteins that select which B cells die and which continue to propagate 42 (Peperzak et al., 2012) . Apoptosis is initiated when BAX and BAK dimerize and permeabilize 43 the mitochondrial outer membrane to release cytochrome C into the cytosol, which activates a 44 cascade of caspases that mediate DNA fragmentation, protein degradation, and cellular 45 blebbing (Fischer et al., 2003) . To prevent aberrant activation, anti-apoptotic proteins bind and 46 sequester BAX and BAK as well as the pro-apoptotic BH3-only proteins (named as such 47 because they share homology in their BH3 domain). Dysregulation of apoptosis typically 48 accompanies the development of lymphomas or autoimmunity, and understanding the 49 mechanisms of apoptosis regulation is key to provide insight and develop new therapeutic 50 strategies for these diseases (Vo et al., 2012) . 51
New breakthroughs in studying apoptosis regulation during B-cell maturation have been 52 made possible by the development of BH3 mimetics, a class of small molecular inhibitors that 53 mimic pro-apoptotic proteins and have shown great promise as cancer therapeutics (Oltersdorf 54 et al., 2005) . In mice, naïve and memory B cells are sensitive to the BH3 mimetic ABT-737, 55 which inhibits BCL-2, BCL-XL, and BCL-W, but pre-existing GC and plasma cells are resistant 56 (Carrington et al., 2010) , suggesting that apoptosis is regulated differently at various stages of 57 B-cell maturation. Recently, human tonsillar GC B cells were found to be sensitive to MCL-1 58 inhibition, which supports previous findings that MCL-1 is essential for GC formation in mice 59 (Peperzak et al., 2017; Vikstrom et al., 2010) . Nonetheless, there remain challenges associated 60 with studying apoptosis in primary human B cells, which have short life-spans in culture, 61 spontaneously undergo apoptosis, and are difficult to transfect. In addition, how apoptotic 62 regulation changes specifically during B-cell activation poorly understood. As a result, we 63 utilized intracellular BH3 (iBH3) profiling to uncover the dominant anti-apoptotic mechanism at 64 the mitochondria of resting and activated primary human B cells. The principles behind iBH3 65 profiling are based upon the selective interactions between the pro-and anti-apoptotic proteins 66 of the Bcl2-family (Deng et al., 2007; Youle and Strasser, 2008) . In short, the anti-apoptotic 67
proteins that are present at the mitochondria dictate which pro-apoptotic BH3-only peptides can 68 induce mitochondrial depolarization and cytochrome C release. In this way, we can identify the 69 anti-apoptotic dependency, or Bcl2-depedency, of the sample. iBH3 profiling can also assay the 70 Bcl2-dependency of multiple populations in heterogeneous samples, thereby eliminating the 71 need for time-consuming and expensive sorting experiments to study rare populations (Ryan et 72 al., 2016) . 73
With the advent of iBH3 profiling and BH3 mimetics, we are equipped with tools that 74 allow us to study how apoptosis is regulated in human B-cell subsets and activated B 75 cells. Therefore, we have used iBH3 profiling to determine the BH3 profiles of normal, resting, 76 and activated B cells, and validated the hypotheses generated by these profiles by treating 77 normal and activated human B-cell subsets with BH3 mimetics. 78
79

Results
80
Naïve and memory B cells circulating in the periphery depend upon BCL-2 for survival 81
To ensure the reliability of iBH3 profiling, we sought to determine the mechanism of 82 apoptosis regulation in peripheral blood B cells from within the bulk PBMC population 83 (Carrington et al., 2010). After staining for cell-specific surface markers, cells were incubated 84 with recombinant BH3-only peptides and digitonin, which selectively permeabilizes the outer 85 cellular membrane and exposes intact mitochondria to the peptide treatment ( Figure 1A) . 86
Following peptide treatment, the cells were fixed, incubated with saponin to permeabilize 87 mitochondria, and stained with a fluorescently-labeled antibody to quantify the remaining levels 88 of intracellular cytochrome C. The extent of cytochrome C release was measured as the 89 dynamic range between total levels of cytochrome C, determined by treating with an inert 90 recombinant PUMA BH3-only peptide (PUMA2A) and alamethicin (Alm), which can induce 91 100% cytochrome C release. 92 Naïve (CD19 + IgD + ) and memory (CD19 + IgD -) B cells were distinguished by IgD 93 expression ( Figure 1B) . iBH3 profiling revealed that the mitochondria in naïve and memory B 94 cells in the peripheral blood were highly sensitive to BIM, BAD, PUMA, and BMF, and relatively 95 resistant to NOXA and HRK ( Figure 1C ). This pattern of sensitivity suggested that naïve and 96 memory B cells were dependent upon BCL-2 for survival ( Figure 1D) . 97
To validate this hypothesis, we treated PBMCs with the following BH3 mimetics: ABT-98 737 (BCL-2, BCL-XL, BCL-W inhibitor), ABT-199 (BCL-2 inhibitor), or WEHI-539 (BCL-XL 99 inhibitor) ( Figure 1E ). Naïve and memory B cells were resistant to WEHI-539 (IC 50 >1 M) and 100 were sensitive to ABT-737 and ABT-199 (IC 50 <1 M), thereby confirming our iBH3 profiling 101 hypotheses and previously published results of BCL-2 dependency ( Figure 1F) . was 102 used to distinguish between BCL-2 and BCL-W, which have identical binding partners ( Figure  103 1D). Staurosporine (STS) is not a BH3 mimetic, but rather it is a pan-kinase inhibitor that 104 induces apoptosis and was used here to distinguish cells that can undergo apoptosis from those 105 that can't, such as cells that lack the effector molecules BAX and BAK (Wei et al., 2001) . 106 B-cell maturation is associated with changes in Bcl-2 family dependency 107
To determine the changes in apoptotic regulation that take place during human B-cell 108 maturation, we queried the apoptotic regulation of CD19 + naïve (IgD + CD38 -), memory (IgD indicates that the perceived sensitivity of the CD38 hi cells to WEHI-539 may not be due to cell 171 death, but rather from a block in differentiation. 172
The overall increase in apoptosis resistance in the CD38 hi subset is not because of 173 impaired BAX and BAK activation, since CD38 hi cells were sensitive to STS, but rather it may be 174 due to an increasing dependence upon MCL-1 as indicated by increasing sensitivity to NOXA in 175 their iBH3 profile. In fact, of the proliferating subsets, only the response of the CD38 hi subset to 176 
Dose-response curves and isobolograms 292
Small molecule inhibitors used in this study were ABT-737 (Selleckchem, S1002), ABT-293 199 (Adooq Biosciences, A12500), WEHI-539 (APExBIO, A3935), A1210477 (Selleckchem, 294 S7790), and staurosporine (Sigma, S5921-0.5MG). Dose-response curves were generated by 295 treating primary cells for 24 hours at 37°C. Mitogen-activated cells were treated on day 3 post-296 stimulation for 3 days and assayed on day 6. Cell counts were performed by flow cytometry and 297 proteins that leads to cytochrome C release. E) Dose-response curves generated from treating 456
PBMCs 
